One Year Post-Launch, The Protease Inhibitors, Incivek and Victrelis have Collectively Penetrated Over Three-Quarters of the US Genotype 1 HCV Market
Incivek Accounts for a Significantly Larger Proportion of Market Share than Victrelis, According to New Research From BioTrends Research Group
EXTON, Pa., Jun 06, 2012 (BUSINESS WIRE) -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that Vertex's Incivek (telaprevir) and Merck / Roche's Victrelis (boceprevir) have staked their claim as the standard of care in US genotype 1 hepatitis C virus (HCV) patients, with 96 percent of surveyed physicians reporting trial with at least one of the protease inhibitors (PIs). According to the recently released LaunchTrends(R): Incivek and Victrelis, Wave 4 report, since their launch one year ago, the PIs have penetrated over three-quarters of the genotype 1 HCV market. Though share for each PI has significantly increased since prior waves, current physician estimates have Incivek accounting for significantly more of the U.S. PI market than Victrelis.
After one year on the market, physician reports suggest Incivek has a slight advantage over Victrelis as the preferred PI in the genotype 1 HCV population. The 100 physicians (gastroenterologists, hepatologists and infectious disease specialists) included in this survey report significantly higher satisfaction with Incivek over Victrelis. Furthermore, physicians perceive that Incivek significantly outperforms Victrelis on the top four most important attributes of 'high SVR in genotype 1s,' 'high SVR in treatment naive patients,' 'high SVR in prior treatment failures' and 'supported by clinical data.' Although both PIs outperform dual therapy on the risk-benefit ratio, Incivek is ranked significantly better than Victrelis in terms of benefits of treatment outweighing the associated risks.
Physicians report that neither PI performs well on any of the associated side effects with triple therapy (anemia, rash, fatigue, etc.). Although Victrelis performs significantly better than Incivek on the side effects of rash, urticarial and pruritis, reported discontinuation rates, roughly 25 percent of all initiations, as well as the primary reasons for discontinuation, are very similar across the two products.
Though the majority of surveyed physicians agree that the PIs, Incivek and Victrelis, are important advances for the treatment of HCV and are a welcomed treatment option, they also highly agree that there remains a need for alternative therapies in the treatment and management of HCV. With regard to products in development, surveyed physicians report the greatest familiarity with Gilead's GS-7977, a significant increase over Wave 2, followed by Bristol-Myers Squibb's daclatasvir, Vertex's VX-222, Bristol-Myers Squibb's asunaprevir and Tibotec / Medivir's TMC-435.
LaunchTrends:
Incivek and Victrelis, Wave 4 is a series of four post-launch syndicated reports designed to track the uptake of Vertex's Incivek and Merck / Roche's Victrelis at one month, three months, six months and one year post-launch. LaunchTrends assesses the trial and use of new products, barriers to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction
Analysis of Incivek (Incivo) and Victrelis in the EU is available via the TreatmentTrends(R):
Hepatitis C in the EU report, which published in May 2012. Additional analysis of the U.S. hepatitis C market will be covered in TreatmentTrends: Hepatitis C in the U.S., a two-wave report series publishing in June and November 2012. Patient level audit analysis of hepatitis C patients is covered in ChartTrends(R): Hepatitis C in the U.S., publishing in July 2012. And finally the patient perspective and role of the patient in treatment selection is analyzed in PatientTrends(R): Hepatitis C, publishing in December 2012.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com .
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com .
All company, brand, or product names contained in this document may be trademarks of their respective holders.
SOURCE: BioTrends Research Group
BioTrends Research Group, LLC
Lynn Price, 610-321-9425
lprice@bio-trends.com
or
Decision Resources Group
Lisa Osgood, 781-993-2606
losgood@dresourcesgroup.com
Copyright Business Wire 2012 http://www.marketwatch.com/story/one-year-post-launch-the-protease-inhibitors-incivek-and-victrelis-have-collectively-penetrated-over-three-quarters-of-the-us-genotype-1-hcv-market-2012-06-06
No comments:
Post a Comment